Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     

  • CRUDE OIL

    83.83
    +0.26 (+0.31%)
     

  • Bitcoin CAD

    87,997.59
    +259.61 (+0.30%)
     

  • CMC Crypto 200

    1,390.76
    +8.19 (+0.59%)
     

  • GOLD FUTURES

    2,345.00
    +2.50 (+0.11%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,765.00
    +197.50 (+1.12%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Biomerica to Participate at BTIG Biotech Conference

Biomerica, Inc.
·1 min read
Biomerica, Inc.
Biomerica, Inc.

IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company’s CEO will also be available for in-person one-on-one meetings at the conference.

About Biomerica NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

CONTACT INFORMATION

John Nesbett / Jennifer Belodeau
IMS Investor Relations
203.972.9200
jnesbett@institutionalms.com